While combination treatment with anti-PD-L1 and docetaxel only decreased tumor growth by 66%, the combination of anti-PD-L1 and TH1902 produced a stronger decrease in tumor size, showing tumor regression at day 11 (regression of 30% compared to initial tumor volume at treatment initiation). This evidence concerns the gene CD274 and neoplasm.